Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 24;33(13):1608-13.
doi: 10.1016/j.vaccine.2015.01.084. Epub 2015 Feb 11.

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012

Susan Hariri  1 , Nancy M Bennett  2 , Linda M Niccolai  3 , Sean Schafer  4 , Ina U Park  5 , Karen C Bloch  6 , Elizabeth R Unger  7 , Erin Whitney  8 , Pamela Julian  9 , Mary W Scahill  10 , Nasreen Abdullah  11 , Diane Levine  12 , Michelle L Johnson  13 , Martin Steinau  14 , Lauri E Markowitz  15 ; HPV-IMPACT Working Group
Collaborators, Affiliations

Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012

Susan Hariri et al. Vaccine. .

Abstract

Background: Prevention of pre-invasive cervical lesions is an important benefit of HPV vaccines, but demonstrating impact on these lesions is impeded by changes in cervical cancer screening. Monitoring vaccine-types associated with lesions can help distinguish vaccine impact from screening effects. We examined trends in prevalence of HPV 16/18 types detected in cervical intraepithelial neoplasia 2, 3, and adenocarcinoma in situ (CIN2+) among women diagnosed with CIN2+ from 2008 to 2012 by vaccination status. We estimated vaccine effectiveness against HPV 16/18-attributable CIN2+ among women who received ≥1 dose by increasing time intervals between date of first vaccination and the screening test that led to detection of CIN2+ lesion.

Methods: Data are from a population-based sentinel surveillance system to monitor HPV vaccine impact on type-specific CIN2+ among adult female residents of five catchment areas in California, Connecticut, New York, Oregon, and Tennessee. Vaccination and cervical cancer screening information was retrieved. Archived diagnostic specimens were obtained from reporting laboratories for HPV DNA typing.

Results: From 2008 to 2012, prevalence of HPV 16/18 in CIN2+ lesions statistically significantly decreased from 53.6% to 28.4% among women who received at least one dose (Ptrend<.001) but not among unvaccinated women (57.1% vs 52.5%; Ptrend=.08) or women with unknown vaccination status (55.0% vs 50.5%; Ptrend=.71). Estimated vaccine effectiveness for prevention of HPV 16/18-attributable CIN2+ was 21% (95% CI: 1-37), 49% (95% CI: 28-64), and 72% (95% CI: 45-86) in women who initiated vaccination 25-36 months, 37-48 months, and >48 months prior to the screening test that led to CIN2+ diagnosis.

Conclusions: Population-based data from the United States indicate significant reductions in CIN2+ lesions attributable to types targeted by the vaccines and increasing HPV vaccine effectiveness with increasing interval between first vaccination and earliest detection of cervical disease.

Keywords: CIN; Cervical intraepithelial neoplasia; HPV; High grade cervical lesion; Human papillomavirus; Vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

L. Niccolai was a consultant/advisory board member for Merck. All other authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Flow chart of women studied from the HPV-IMPACT project.
Fig. 2.
Fig. 2.
HPV 16/18 attribution to CIN2+ lesions among women age-eligible for vaccination, by year and vaccination status. Abbreviations: CIN2+; cervical intraepithelial neoplasia grades 2; 3 and adenocarcinoma in situ (AIS). aVaccinated includes women vaccinated >30 days before trigger test (screening test that led to CIN2+ diagnosis).
See this image and copyright information in PMC

Comment in

References

    1. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl. 3). S3/1-10. - PubMed
    1. Franco EL, Olsen J, Saracci R, Detels R. Epidemiology’s contributions to a Nobel Prize recognition. Epidemiology 2009;20:632–4. - PubMed
    1. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11:1048–56. - PubMed
    1. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agents Cancer 2012;7:38. - PMC - PubMed
    1. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493. - PMC - PubMed

Publication types

MeSH terms

Substances